CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Jan. 31, 2023		214,293
Beginning balance at Jan. 31, 2023	$ 356,574	$ 2	$ 1,595,001	$ (873)	$ (1,237,556)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of options (in shares)		2,101
Issuance of common stock upon the exercise of options	4,843		4,843
Vesting of early exercised stock options	109		109
Issuance of common stock upon the vesting and settlement of restricted stock units (in shares)		7,456
Issuance of common stock upon the vesting and settlement of restricted stock units	(10)		(10)
Issuance of common stock under employee share purchase plan (in shares)		878
Issuance of common stock under employee share purchase plan	15,069		15,069
Stock-based compensation expense	206,204		206,204
Net unrealized gains (losses) on marketable securities	679			679
Foreign currency translation adjustments	(42)			(42)
Net loss	(257,030)				(257,030)
Ending balance (in shares) at Jan. 31, 2024		224,728
Ending balance at Jan. 31, 2024	326,396	$ 2	1,821,216	(236)	(1,494,586)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of options (in shares)		3,716
Issuance of common stock upon the exercise of options	9,101		9,101
Vesting of early exercised stock options	0
Repurchases and retirement of common stock (in shares)		(6,213)
Repurchases and retirement of common stock	(78,354)				(78,354)
Issuance of common stock upon the vesting and settlement of restricted stock units (in shares)		9,538
Issuance of common stock upon the vesting and settlement of restricted stock units	(5)		(5)
Issuance of common stock under employee share purchase plan (in shares)		1,119
Issuance of common stock under employee share purchase plan	13,665		13,665
Stock-based compensation expense	215,871		215,871
Net unrealized gains (losses) on marketable securities	(2)			(2)
Foreign currency translation adjustments	(3,613)			(3,613)
Net loss	(255,536)				(255,536)
Ending balance (in shares) at Jan. 31, 2025		232,888
Ending balance at Jan. 31, 2025	$ 227,523	$ 2	2,059,848	(3,851)	(1,828,476)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of options (in shares)	1,714	1,714
Issuance of common stock upon the exercise of options	$ 5,021		5,021
Vesting of early exercised stock options	0
Repurchases and retirement of common stock (in shares)		(9,725)
Repurchases and retirement of common stock	(132,206)				(132,206)
Issuance of common stock upon the vesting and settlement of restricted stock units (in shares)		11,786
Issuance of common stock upon the vesting and settlement of restricted stock units	0
Issuance of common stock under employee share purchase plan (in shares)		1,252
Issuance of common stock under employee share purchase plan	13,012		13,012
Stock-based compensation expense	221,735		221,735
Net unrealized gains (losses) on marketable securities	469			469
Foreign currency translation adjustments	7,587			7,587
Net loss	(189,024)				(189,024)
Ending balance (in shares) at Jan. 31, 2026		237,915
Ending balance at Jan. 31, 2026	$ 154,117	$ 2	$ 2,299,616	$ 4,205	$ (2,149,706)